Does Zoledronic Acid Have Additive Effect on Suppression of Plasma Estrogen Levels ? |
Sendur, Mehmet Ali Nahit
(Ankara Numune Education and Research Hospital)
Aksoy, Sercan (Hacettepe University Cancer Institute, Department of Medical Oncology) Ozdemir, Nuriye Yildirim (Ankara Numune Education and Research Hospital) Akinci, Muhammed Bulent (Ankara Numune Education and Research Hospital) Zengin, Nurullah (Ankara Numune Education and Research Hospital) Altundag, Kadri (Hacettepe University Cancer Institute, Department of Medical Oncology) |
1 | Pfeiler G, Königsberg R, Fesl C, et al (2011). Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol, 29, 2653-9. DOI ScienceOn |
2 | Santini D, Vincenzi B, Galluzzo S, et al (2007). Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res, 13, 4482-6. DOI ScienceOn |
3 | Schech AJ, Nemieboka BE, Brodie AH (2012). Zoledronic acid inhibits aromatase activity and phosphorylation: Potential mechanism for additive zoledronic acid and letrozole drug interaction. J Steroid Biochem Mol Biol, 132, 195-202. DOI ScienceOn |
4 | Brufsky A, Harker WG, Beck JT, et al (2007). Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol, 25, 829-36. DOI ScienceOn |
5 | Eidtmann H, de Boer R, Bundred N, et al (2010). Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol, 21, 2188-94. DOI ScienceOn |
6 | Folkerd EJ, Dixon JM, Renshaw L, A'Hern RP, Dowsett M (2012). Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol, 30, 2977-80. DOI |
7 | Gnant M, Mlineritsch B, Luschin-Ebengreuth G (2008). Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol, 9, 840-9. DOI ScienceOn |
8 | Gnant M, Mlineritsch B, Schippinger W, et al. (2009). Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med, 360, 679-91. DOI ScienceOn |
9 | Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al (2007). Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol, 25, 820-8. DOI ScienceOn |
10 | Kunzmann V, Bauer E, Feurle J, et al (2000). Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood, 96, 384-92. |
![]() |